Association between the TP53BP1 rs2602141 A/C Polymorphism and Cancer Risk: A Systematic Review and Meta-Analysis |
Liu, Lei
(Department of Ophthalmology, The First Affiliated Hospital, China Medical University)
Zhang, Dong (Department of General Surgery, the Fourth People's Hospital of Shenyang) Jiao, Jing-Hua (Department of Anesthesiology, Fengtian Hospital, Shenyang Medical College) Wang, Yu (Department of Development and Planning Office, School of Public Health, China Medical University) Wu, Jing-Yang (Department of Ophthalmology, The First Affiliated Hospital, China Medical University) Huang, De-Sheng (Department of Epidemiology, School of Public Health, China Medical University) |
1 | Williams RS, Green R, Glover JN (2001). Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1. Nat Struct Biol, 8, 838-42. DOI ScienceOn |
2 | Zhang H, Hao S, Zhao J, et al (2013). Common Genetic Variants in 53BP1 Associated with Non-small Cell Lung Cancer Risk in Han Chinese. Arch Med Res, 45, 84-9. |
3 | Zhao L, Zhao X, Wu X, Tang W (2013). Association of p53 Arg72Pro polymorphism with esophageal cancer: a meta-analysis based on 14 case-control studies. Genet Test Mol Biomarkers, 17, 721-6. DOI ScienceOn |
4 | Miwa S, Tome Y, Yano S, et al (2013). Single cell time-lapse imaging of focus formation by the DNA damage-response protein 53BP1 after UVC irradiation of human pancreatic cancer cells. Anticancer Res, 33, 1373-7. |
5 | Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 6, 1000097. DOI ScienceOn |
6 | Ma H, Hu Z, Zhai X, et al (2006). Joint effects of single nucleotide polymorphisms in P53BP1 and p53 on breast cancer risk in a Chinese population. Carcinogenesis, 27, 766-71. |
7 | Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48. |
8 | Naidu R, Har YC, Taib NA (2011). Genetic polymorphisms of TP53-binding protein 1 (TP53BP1) gene and association with breast cancer risk. APMIS, 119, 460-7. DOI ScienceOn |
9 | Rappold I, Iwabuchi K, Date T, Chen J (2001). Tumor suppress or p53 binding protein1 (53BP1) is involved in DNA damagesignaling pathways. J Cell Biol, 153, 613-20. DOI ScienceOn |
10 | Rauch T, Zhong X, Pfeifer GP, Xu X (2005). 53BP1 is a Positive Regulator of the BRCA1 Promoter. Cell Cycle, 4, 1078-83. |
11 | Rudd MF, Webb EL, Matakidou A, et al (2006). Variants in the GH-IGF axis confer susceptibility to lung cancer. Genome Res, 16, 693-701. DOI ScienceOn |
12 | DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. DOI ScienceOn |
13 | Camargo MC, Mera R, Correa P, et al (2006). Interleukin-1 beta and interleukin-1 receptor antagonistgene polymorphisms and gastric cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev, 15, 1674-87. DOI ScienceOn |
14 | Chen K, Hu Z, Wang LE, et al (2007). Polymorphic TP53BP1 and TP53 gene interactions associated with risk of squamous cell carcinoma of the head and neck. Clin Cancer Res, 13, 4300-5. DOI ScienceOn |
15 | DerSimonian R, Kacker R (2007). Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials, 28, 105-14. DOI ScienceOn |
16 | Egger M, Davey SG, Schneider M, et al (1997). Bias in metaanalysis detected by a simple, graphical test. BMJ, 315, 629-34. DOI ScienceOn |
17 | Ferlay J, Shin HR, Bray F, et al (2010). Estimates of world wide burden of cancer in 2008 : GLOBO CAN 2008. Int J Cancer, 127, 2893-917. DOI ScienceOn |
18 | Frank B, Hemminki K, Bermejo JL, et al (2005). TP53-binding protein variants and breast cancer risk: a case-control study. Breast Cancer Res, 7, 502-5. DOI ScienceOn |
19 | Gao LB, Pan XM, Li LJ, et al (2011). RAD 51135G/C polymorphism and breast cancer risk: a meta-analysis from 21 studies. Breast Cancer Res Treat, 125, 827-35. DOI |
20 | He C, Nan H, Qureshi AA, Han J (2010). Genetic variants in the 53BP1 gene and skin cancer risk. J Invest Dermatol, 130, 2850-3. DOI ScienceOn |
21 | Liu GY, Jiang DK, Shen SQ, Yu L (2011). MDM2 SNP309T.>G polymorphism with hepatocellular carcinoma risk: a metaanalysis. Arch Med Res, 42, 149-55. DOI ScienceOn |
22 | Wang B, Matsuoka S, Carpenter PB, Elledge SJ (2002). 53BP1, a mediator of the DNA damage checkpoint. Science, 298, 1435-8. DOI ScienceOn |
23 | Weng Y, Lu L, Yuan G, et al (2012). p53 codon 72 polymorphism and hematological cancer risk: an update meta-analysis. PLoS One, 7, 45820. DOI |
24 | Schultz LB, Chehab NH, Malikzay A, Halazonetis TD (2000). p53 binding protein 1 (53BP1) is an early participant in the cellular response to DNA double-strand breaks. J Cell Biol, 151, 1381-90. DOI ScienceOn |
25 | Truong T, Sauter W, Mc Kay JD, et al (2010). International Lung Cancer Consortium: coordinated association study of 10 potential lung cancer susceptibility variants. Carcinogenesis, 31, 625-33. DOI ScienceOn |
26 | DiTullio RA Jr, Mochan TA, Venere M, et al (2002). P53BP 1 functions in an ATM dependent checkpoint pathway that is constitutively activated in human cancer. Nat Cell Biol, 4, 998-1002. DOI ScienceOn |
![]() |